Acquired Company
Collegium Pharmaceutical, Inc. completed the acquisition of BioDelivery Sciences International, Inc. for $5.60 per share in cash on March 22, 2022, valuing the transaction at approximately $604 million.
BioDelivery Sciences International, Inc. is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI has built a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. BDSI's marketed products address serious and debilitating conditions, including chronic pain and opioid-induced constipation. Show more
Location: 4131 Parklake Ave Ste 225, North Carolina, 27612-2390, US | Website: www.bdsi.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
0.00
52 Wk Range
$N/A - $N/A
Previous Close
$5.60
Open
$5.60
Volume
2,090,567
Day Range
$5.59 - $5.60
Enterprise Value
0.00
Cash
0.00
Avg Qtr Burn
N/A
Insider Ownership
0.00%
Institutional Own.
0.00%
Qtr Updated
06/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|
